Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious infection events in rheumatoid arthritis patients treated with conventional disease-modifying anti-rheumatic drugs: A cohort study in the treat-to-target era

Clinical and Experimental Rheumatology

Volumn 34, Issue 2, 2016, Pages 261-269

  Galicia Hernández, Gretel ^a   Parra Salcedo, Federico ^a   Ugarte Martínez, Paulina ^a   Contreras Yáñez, Irazú ^a   Ponce de León, Alfredo ^a   Pascual Ramos, Virginia ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Anti rheumatic agents; Comorbidity; Infection; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ANTIRHEUMATIC AGENT;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BACTEREMIA; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENINGITIS; MEXICAN; OUTCOME ASSESSMENT; PERIODONTAL DISEASE; PHYSICAL DISABILITY; PNEUMOCOCCAL INFECTION; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SOFT TISSUE INFECTION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADOLESCENT; ARTHRITIS, RHEUMATOID; CHILD; COMPLICATION; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHILD; COHORT STUDIES; FEMALE; HUMANS; INFECTION; LOGISTIC MODELS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 84963795551     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. SMITTEN AL, CHOI HK, HOCHBERG MC et al.: The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 387-93
2. DORAN MF, CROWSON CS, POND GR, ÓFALLON WM, GABRIEL SE: Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300
3. SOKKA T, ABELSON B, PINCUS T: Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26: S35-61
4. THOMAS E, SYMMONS DB, BREWSTER DH et al.: National study of all cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year follow-up study. J Rheumatol 2003; 30: 958-65
5. CAPORALI R, CAPRIOLI M, BOBBIO-PALLAVICINI F, MONTECUCCO C: DMARDS and infections in rheumatoid arthritis. Autoimmun Rev 2008; 8: 139-43
6. DORAN MF, CROWSON CS, POND GR, ÓFALLON M, GABRIEL SE: Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum 2002; 46: 2287-93
7. WOLFE F, CAPLAN L, MICHAUD K: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease modifying anti-rheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628-34
8. MIKULS TR: Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17: 729-52
9. KAREN AU, REED G, CUSTIS J et al.: High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 785-91
10. WEAVER A, TROUM O, HOOPER M et al.: Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1. J Rheumatol 2013; 40: 1275-81
11. JENKS KA, STAMP LK, O'DONNELL JL, SAVAGE RL, CHAPMAN PT: Leflunomide associated infections in rheumatoid arthritis. J Rheumatol 2007; 34: 2201-3
12. BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step down prednisolone, methotrexate, sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18
13. FERRACIOLI GF, GREMESE E, TOMIETTO P, FAVRET G, DAMATO R, DI PE: Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporine A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002; 41: 892-8
14. PASCUAL-RAMOS V, CONTRERAS-YáñEZ I, VILLA AR, CABIEDES J, RULL-GABAYET M: Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and disability. Arthritis Res Ther 2009; 11: R26
15. CONTRERAS-YáñEZ I, PONCE DE LEóN S, CABIEDES J, RULL-GABAYET M, PASCUALRAMOS V: Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 2010; 340: 282-90
16. CONTRERAS-YáNEZ I, RULL-GABAYET M, PASCUAL-RAMOS V: Early disease activity suppression and younger age predict excellent outcome of recent-onset rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs. Clin Exp Rheumatol 2012; 30: 402-8
17. MODY GM, CARDIEL MH: Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol 2008; 22: 621-41
18. COHEN S: Social status and susceptibility to respiratory infections. Ann NY Acad Sci 1999; 896: 246-53
19. FLORY JH, JOFFE M, FISHMAN NO, EDELSTEIN PH, METLAY JP: Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults. Epidemiol Infect 2009; 137: 717-26
20. CONTRERAS-YáñEZ I, CABIEDES J, VILLA AR, RULL-GABAYET M, PASCUAL-RAMOS V: Persistence on therapy is a major determinant of patient-, physician-and laboratoryreported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol 2010; 28: 748-51
21. ALETAHA D, WARD MM, MACHOLD KP, NELL VPK, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis. Defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625-36
22. US Food and Drug Administration: Code of Federal Regulation Title 21. Section 312.32 Investigational new drug application safety reporting. Definitions. 21CFR312.32 (Internet. Accessed March 5, 201)
23. HERNáNDEZ-CRUZ, CARDIEL MH, VILLA AR, ALCOCER-VARELA J: Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 1998; 25: 1900-7
24. EMERY P, GALLO G, MORGAN C, CURRIES C, POOLE C, NAB H: Evaluation of the association between disease activity and risk of serious infections in subjects with rheumatoid arthritis when treated with etarnecept or disease modifying anti-rheumatic drugs. Arthritis Rheum 2011; 63 (Suppl.): S163
25. LACAILLE D, GUH DP, ABRAHAMOWICZ M, ANIS A, ESDIALE J: Use of nonbiologic disease modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 1074-81
26. DIXON WG, KEZOUH A, BERNATSKY S, SUISSA S: The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011; 70: 956-60
27. STUCK AE, MINDER CE, FREY FJ: Risk of infectious complications in patients taking glucocorticosteroids. Rev Infec Dis 1989; 11: 954-63
28. CROWSON CS, HOGANSON DD, FTIZ-GIBBON PD, MATTESON EL: Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2847-55
29. CHARLSON ME, POMPEI P, ALES KL, Mac-KENZIE R: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-83
30. YURKOVICH M, AVINA-ZUBIETA A, THOMAS J, GORENCHTEIN M, LACAILLE D: A systematic review identifies valid comorbidity indices derived from administrative health data. J Clin Epidemiol 2015; 68: 3-14
31. KROESEN A, WIDMER AF, TYNDALL A, HASLER P: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology 2003; 42: 617-21
32. LAMPROPOULOS CE, ORFANOS P, BOURNIA V-K et al.: Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologics agents: a real word study. Clin Exp Rheumatol 2015; 33: 216-24
33. BERNATSKY S, HUDSON M, SUISSA S: Antirheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007; 46: 1157-60
34. van DARTEL SAA, FRANSEN J, KIEVIT W et al.: Predictors of the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012; 52: 1052-7
35. REILLY PA, COSH JA, MADDISON PJ, RASKER JJ, SILMAN AJ: Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990; 49: 363-9
36. GONZáLEZ A, MARADIT KREMERS M, CROWSON CS et al.: The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56: 3583-7
37. MUTRU O, LAAKSO M, ISOMAKI H, KOOTA K: Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985; 290: 1797-9
38. MYLLYKANGAS-LUOSUJARVI R, AHO K, KAUTIAINEN H, ISOMAKI H: Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 149-53
39. PRIOR P, SYMMONS DP, SCOTT DL, BROWN R, HAWKINS CF: Cause of death in rheumatoid arthritis. Br J Rheumatol 1984; 23: 92-9
40. CARMONA L, GONZáLEZ-ALVARO I, SANMARTí R et al.; EMECAR Study Group: Rheumatoid arthritis is associated to a fourfold increase in tuberculosis infection incidence in the pre-biologics era [abstract]. Arthritis Rheum 2001; 44: S173
41. GREENBERG SB: Infections in immunocompromised rheumatologic patient. Crit Care Clin 2002; 18: 931-56
42. CARDIEL MH, DíAZ-BORJóN A, VáZQUEZ DEL MERCADO ESPINOSA M et al.: Actualización de la guía mexicana para el tratamiento farmacológico de la artritis reumatoide del Colegio Mexicano de Reumatología. Reumatol Clin 2014; 10: 227-40